Sun launches favipiravir at `35 per tablet

Sun Pharmaceutical Industries said it has launched antiviral drug favipiravir under the brand name 'FluGuard' for the treatment of mild to moderate cases of Covid-19, at Rs 35 per tablet in India. The stocks of FluGuard will be available in the market from this week, Sun said in a regulatory filing. Favipiravir is the only oral anti-viral treatment approved in India for the treatment of patients with mild to moderate Covid-19, it added.